熱門資訊> 正文

Neurogene GAAP每股收益为-1.05美元

2025-08-12 04:50

Neurogene press release (NASDAQ:NGNE): Q2 GAAP EPS of -$1.05.
Cash, Cash Equivalents and Short-Term Investments: Cash, cash equivalents and short-term investments as of June 30, 2025 were $274.5 million. We currently expect cash, cash equivalents and short-term investments to fund planned operations into early 2028.

More on Neurogene

Neurogene downgraded to Neutral at Baird on regulatory uncertainty
Seeking Alpha’s Quant Rating on Neurogene
Historical earnings data for Neurogene
Financial information for Neurogene

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。